NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say.
NCI Cancer Bulletin publicized board’s resignation over liability concerns.
NCI reassigns project officer John Gohagan.
Also in this 8-page issue: NCI, FDA open Web site for adverse event reporting.
Kansas Cancer Institute gets $15 million pledge, is renamed, and hires a new director in effort to win NCI center grant.
Funding opportunities listed.
Trending Stories
- CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot
- Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.” - Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Team USA’s Julie Letai competes in Milan Olympics speed skating event









